Stock Track | Kymera Therapeutics Plummets 7.27% in Early Trading on Disappointing Q4 Results

Stock Track

Feb 27, 2025

Kymera Therapeutics, Inc. (KYMR) stock plunged 7.27% in early Thursday trading following the release of its disappointing fourth-quarter results. The biopharmaceutical company reported a wider net loss and lower collaboration revenue compared to the year-ago period, missing analyst estimates.

For the quarter ended December 31, 2024, Kymera Therapeutics posted a net loss of $0.88 per diluted share, significantly worse than the $0.25 loss in the same period a year earlier. The company's collaboration revenue for the quarter came in at $7.4 million, a substantial decrease from $47.9 million in the prior-year quarter. Both figures missed consensus analyst estimates.

The company highlighted its strong cash position of $851 million as of December 31, which is expected to fund operations into mid-2027. However, investors appeared to focus on the disappointing quarterly performance, driving the stock down in pre-market trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1118306033"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118306033\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118306033?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 23:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118306033","market":"us","top_or_hot":-1,"title":"Stock Track | Kymera Therapeutics Plummets 7.27% in Early Trading on Disappointing Q4 Results","media":"Stock Track","content":"<p>Kymera Therapeutics, Inc. (KYMR) stock plunged 7.27% in early Thursday trading following the release of its disappointing fourth-quarter results. The biopharmaceutical company reported a wider net loss and lower collaboration revenue compared to the year-ago period, missing analyst estimates.</p>\n\n<p>For the quarter ended December 31, 2024, Kymera Therapeutics posted a net loss of $0.88 per diluted share, significantly worse than the $0.25 loss in the same period a year earlier. The company's collaboration revenue for the quarter came in at $7.4 million, a substantial decrease from $47.9 million in the prior-year quarter. Both figures missed consensus analyst estimates.</p>\n\n<p>The company highlighted its strong cash position of $851 million as of December 31, which is expected to fund operations into mid-2027. However, investors appeared to focus on the disappointing quarterly performance, driving the stock down in pre-market trading.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kymera Therapeutics Plummets 7.27% in Early Trading on Disappointing Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kymera Therapeutics Plummets 7.27% in Early Trading on Disappointing Q4 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 23:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kymera Therapeutics, Inc. (KYMR) stock plunged 7.27% in early Thursday trading following the release of its disappointing fourth-quarter results. The biopharmaceutical company reported a wider net loss and lower collaboration revenue compared to the year-ago period, missing analyst estimates.</p>\n\n<p>For the quarter ended December 31, 2024, Kymera Therapeutics posted a net loss of $0.88 per diluted share, significantly worse than the $0.25 loss in the same period a year earlier. The company's collaboration revenue for the quarter came in at $7.4 million, a substantial decrease from $47.9 million in the prior-year quarter. Both figures missed consensus analyst estimates.</p>\n\n<p>The company highlighted its strong cash position of $851 million as of December 31, which is expected to fund operations into mid-2027. However, investors appeared to focus on the disappointing quarterly performance, driving the stock down in pre-market trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KYMR","symbol_name":"Kymera Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1118306033","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118306033","pubTimestamp":1740669006,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Kymera Therapeutics, Inc.  stock plunged 7.27% in early Thursday trading following the release of its disappointing fourth-quarter results. The biopharmaceutical company reported a wider net loss and lower collaboration revenue compared to the year-ago period, missing analyst estimates.For the quarter ended December 31, 2024, Kymera Therapeutics posted a net loss of $0.88 per diluted share, significantly worse than the $0.25 loss in the same period a year earlier. The company's collaboration rev","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KYMR":"Kymera Therapeutics, Inc."},"translate_title":"股票赛道Kymera Therapeutics因第四季度业绩令人失望而早盘暴跌7.27%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYMR":1},"content_text":"Kymera Therapeutics, Inc. (KYMR) stock plunged 7.27% in early Thursday trading following the release of its disappointing fourth-quarter results. The biopharmaceutical company reported a wider net loss and lower collaboration revenue compared to the year-ago period, missing analyst estimates.\nFor the quarter ended December 31, 2024, Kymera Therapeutics posted a net loss of $0.88 per diluted share, significantly worse than the $0.25 loss in the same period a year earlier. The company's collaboration revenue for the quarter came in at $7.4 million, a substantial decrease from $47.9 million in the prior-year quarter. Both figures missed consensus analyst estimates.\nThe company highlighted its strong cash position of $851 million as of December 31, which is expected to fund operations into mid-2027. However, investors appeared to focus on the disappointing quarterly performance, driving the stock down in pre-market trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}